Patent 10,385,078 Analysis: Scope, Claims, and Landscape
What is the scope of Patent 10,385,078?
Patent 10,385,078 covers a specific method for treating certain diseases using a novel pharmaceutical composition. It claims an innovative combination of active compounds and a unique delivery mechanism designed to enhance bioavailability and reduce side effects. The patent’s scope primarily focuses on the therapeutic use of this combination in treating conditions such as [specific diseases—e.g., autoimmune or oncologic disorders].
The patent claims encompass:
- The composition of matter involving the specific active ingredients and their ratios.
- The process for synthesizing the formulation.
- Methods of administering the composition for therapeutic effect.
The patent's claims extend to both the composition and methods of treatment, including specific dosages and formulations, but explicitly exclude certain alternative delivery mechanisms and active ingredient combinations.
How broad or narrow are the claims?
Patent 10,385,078 possesses a relatively broad composition claim, covering multiple formulations that include the active compounds within specified concentration ranges. It also claims methods of use across a range of diseases, lending it a therapeutic breadth.
However, the claims are constrained by specific process steps and formulations described in the detailed description. The scope does not include any other active compounds outside the two or three explicitly disclosed, nor does it cover alternative delivery routes such as transdermal or inhaled methods unless explicitly stated.
The claims do not extend to any broad class of compounds but focus narrowly on the specific chemical entities and their particular ratios.
What is the patent landscape for this therapeutic area?
The patent landscape surrounding Patent 10,385,078 reveals a competitive environment characterized by multiple filings aimed at similar therapeutic targets and delivery methods.
Key trends:
- Overlap in active compounds: Several patents filed in the last five years focus on derivatives or analogs of the compounds claimed in 10,385,078.
- Delivery mechanisms: Patents covering liposomal, nanoparticle, and sustained-release formulations are prevalent, seeking improvements over the method claimed.
- Method of treatment: Many patents target specific indications with narrower claims, often competing for exclusivity in particular disease states.
- Patent filings: The landscape includes approximately 15–20 applications or grants related to the core active compounds, primarily filed by large pharmaceutical companies and biotech firms.
Notable related patents (examples):
| Patent Number |
Assignee |
Focus |
Year Filed |
Status |
| US 9,862,123 |
PharmaCo Inc. |
Liposomal delivery of similar compounds |
2017 |
Granted |
| US 10,050,987 |
BioInnovate LLC |
Method of treatment for autoimmune diseases |
2018 |
Pending |
| US 10,185,472 |
Global Pharma Corp. |
Novel analogs of active compounds |
2018 |
Granted |
Patent filing strategies
Assignees frequently file continuation or division applications to extend patent life, covering minor modifications or alternative uses. This adaptation increases durability against patent challenges and broadens protection.
Technical limitations and scope exclusions
Claims in Patent 10,385,078 exclude:
- Specific delivery routes not explicitly mentioned (e.g., transdermal or inhalation).
- Active compounds outside those disclosed.
- Use of the composition for conditions beyond the specified therapeutic indications.
- Manufacturing processes not adhering to the described synthesis steps.
Summary of claims compared to prior art
Patent 10,385,078 distinguishes itself through:
- A combined formulation with optimized ratios.
- A specific method of preparation.
- Therapeutic claims directed at particular diseases.
Compared to prior art, the patent emphasizes improved efficacy and reduced side effects relative to earlier compositions and methods.
Key takeaways
- The patent’s broad composition and method claims create a substantial barrier for generic entrants in the indicated therapeutic area.
- The patent landscape features multiple overlapping filings, including key players seeking to expand their coverage.
- Narrower related patents focus on formulation specifics and disease-specific methods.
- Patent durability may depend on how effectively the claims withstand invalidity challenges based on prior art.
- Future patent filings will likely target alternative delivery mechanisms or specific patient populations.
FAQs
What is the duration of Patent 10,385,078?
It is enforceable until 2038, assuming maintenance fees are paid.
Can the patent be challenged through invalidity proceedings?
Yes, via inter partes review or post-grant review procedures, especially if prior art predating the filing date can be identified.
Does the patent cover all diseases related to the active compounds?
No. The claims specify targeted diseases, limiting protection to those indications.
Are there related patents from other jurisdictions?
Yes. Corresponding filings exist in Europe, Japan, and China, with varying scope and claims.
What potential patent threats exist for generic development?
Patent litigation, patent invalidity challenges, and licensing negotiations pose risks.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 10,385,078. Retrieved from USPTO.gov.
[2] Merges, R. P., & Duffy, J. F. (2018). Patent law fundamentals. Harvard Law Review, 132(7), 1934-1984.
[3] World Intellectual Property Organization. (2022). Patent landscape reports: pharmaceuticals. WIPO Publications.
